Regulatory Approval (ANDA)
FDC Receives USFDA ANDA Approval for Cefixime Oral Suspension
NSE
fdc
BSE
531599
FDC Limited has received ANDA approval from the United States Food and Drug Administration (USFDA) for Cefixime for Oral Suspension USP in strengths of 100 mg/5 mL and 200 mg/5 mL, strengthening its regulated market portfolio in the United States.
PRICE-SENSITIVE TRIGGER
Event: USFDA grants ANDA approval for Cefixime Oral Suspension.
Type: Regulatory Approval (ANDA)
Impact: Positive
Immediate Effect: The approval enables FDC to market the approved generic oral suspension formulations in the US market, subject to commercial launch plans.
Key Metrics:
- ANDA approval received from USFDA.
- Product approved: Cefixime for Oral Suspension USP.
- Approved strengths: 100 mg/5 mL and 200 mg/5 mL.
- Approval expands FDC’s regulated market product basket.
Highlight Metric:
- Key Development: USFDA ANDA approval for Cefixime Oral Suspension formulations.
What Happened ?
FDC Limited informed stock exchanges that it has received Abbreviated New Drug Application (ANDA) approval from the United States Food and Drug Administration (USFDA).
The approval covers Cefixime for Oral Suspension USP in strengths of 100 mg/5 mL and 200 mg/5 mL. The regulatory clearance allows the company to strengthen its presence in the US generic pharmaceutical market.
Key Details
Product Approval Details:
- USFDA granted ANDA approval to FDC Limited.
- Approval pertains to Cefixime Oral Suspension USP.
- Two strengths approved: 100 mg/5 mL and 200 mg/5 mL.
Strategic Importance:
- The approval strengthens FDC’s regulated market portfolio.
- USFDA approvals improve long-term export opportunities and product diversification.
- The development supports the company’s presence in the highly competitive US generics market.
Industry Context:
- ANDA approvals are important for generic pharmaceutical companies seeking entry into regulated markets.
- Oral suspension formulations are widely prescribed in anti-infective therapy segments.
Note:
- The company has not disclosed expected launch timelines, market size, or revenue potential from the approved product.
Risk Analysis
Key Risks:
- Intense pricing competition in the US generics industry.
- Delays in commercial launch could impact revenue realization.
- Margin pressure due to regulatory and compliance costs.
- Dependence on sustained USFDA compliance standards.
Worst Case Scenario:
- If pricing pressure or market competition intensifies significantly, the approved product may generate limited profitability despite regulatory clearance.
Risk Level: Medium
Company Commentary
- FDC has received ANDA approval from the USFDA.
- Approval is for Cefixime for Oral Suspension USP.
- Approved strengths are 100 mg/5 mL and 200 mg/5 mL.
Official Exchange Filing: FDC Limited